Detection of MAGE-A expression predicts malignant transformation of oral leukoplakia

Cancer Investigation

Volumn 30, Issue 7, 2012, Pages 495-502

  Ries, Jutta ^a   Agaimy, Abbas ^a   Vairaktaris, Elefterios ^b   Gorecki, Patricia ^a   Neukam, Friedrich W ^a   Straßburg, Lei H ^a   Nkenke, Emeka ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cancer risk assessment; MAGE A expression; Oral precancerous lesions; OSCC

Indexed keywords

MELANOMA ANTIGEN 1;

ANTIGEN EXPRESSION; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; LEUKOPLAKIA; MALIGNANT TRANSFORMATION; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA, ORAL; MALE; MELANOMA-SPECIFIC ANTIGENS; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS;

EID: 84863887281     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.691191     Document Type: Article

References (40)

1. Gondos A, Arndt V, Holleczek B, Stegmaier C, Ziegler H, Brenner H. Cancer survival in Germany and the United States at the beginning of the 21st century: An up-To-Date comparison by period analysis. Int J Cancer 2007;121:395-400.
2. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Lung T, Tascau OC, Almasan HA, Muresan O. Head and neck cancer, treatment, evolution and post therapeutic survival -Part 2: A decade's results 1993-2002. J Craniomaxillofac Surg 2007;35:126-131.
4. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005;5:127-135.
5. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007;36:575-580.
6. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; Terminology, classification and present concepts of management. Oral Oncol 2009;45:317-323.
7. Reibel J. Prognosis of oral pre-Malignant lesions: Significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 2003;14:47-62.
8. Pitiyage G, Tilakaratne WM, Tavassoli M, Warnakulasuriya S. Molecular markers in oral epithelial dysplasia: Review. J Oral Pathol Med 2009;38:737-752.
9. Pindborg JJ. World Health Organization: Histological Typing of Cancer and Precancer of the Oral Mucosa, Vol. 14. Berlin: Springer-Verlag, 1997, 47-62.
10. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: Predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008;37:127-133.
11. Fleskens S, Slootweg P. Grading systems in head and neck dysplasia: Their prognostic value, weaknesses and utility. Head Neck Oncol 2009;1:1-11.
12. Warnakulasuriya S. Lack of molecular markers to predict malignant potential of oral precancer. J Pathol 2000;190:407-409.
13. Ha PK, Chang SS, Glazer CA, Califano JA, SidranskyD.Molecular techniques and genetic alterations in head and neck cancer. Oral Oncol 2009;45:335-339.
14. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC,Old LJ. Expression ofMAGE-antigens in normal tissues and cancer. Int J Cancer 2000;85:460-465.
15. Jungbluth AA, SilvaWA, Iversen K Jr, Frosina D, Zaidi B, Coplan K, Eastlake-Wade SK, Castelli SB, Spagnoli GC, Old LJ, Vogel M. Expression of cancer-Testis (CT) antigens in placenta. Cancer Immun 2007;7:15.
16. Muller-Richter UD, Dowejko A, Peters S, Rauthe S, Reuther T, Gattenlohner S, Reichert TE, Driemel O, Kubler AC. MAGE-A antigens in patients with primary oral squamous cell carcinoma. Clin Oral Investig 2010;14:291-296.
17. Mollaoglu N, Vairaktaris E, Nkenke E, Neukam FW, Ries J. Expression of MAGE-A12 in oral squamous cell carcinoma. Dis Markers 2008;24:27-32.
18. Ries J, Mollaoglu N, Toyoshima T, Vairaktaris E, Neukam FW, Ponader S, Nkenke E. A novel multiple-Marker method for the early diagnosis of oral squamous cell carcinoma. Dis Markers 2009;27:75-84.
19. Ries J, Schultze-Mosgau S, NeukamF, Diebel E, Wiltfang J. Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy. Int J Oncol 2005;26:817-824.
20. Ries J, Vairaktaris E, Mollaoglu N, Wiltfang J, Neukam FW, Nkenke E. Expression of melanoma-associated antigens in oral squamous cell carcinoma. J Oral Pathol Med 2008;37:88-93.
21. Krauss E, Rauthe S, Gattenlohner S, Reuther T, KochelM, Kriegebaum U, Kubler AC, Muller-Richter UD. MAGE-A antigens in lesions of the oral mucosa. Clin Oral Investig 2010;15:315-320.
22. Metzler P,Mollaoglu N, Schwarz S,NeukamFW, Nkenke E, Ries J. MAGE-A as a novel approach in the diagnostic accuracy of oral squamous cell cancer: A case report. Head Neck Oncol 2009;1:39,45.
23. Ries J, Ponader S, Mollaoglu N, Vairaktaris E, Neukam FW, Nkenke E. Early findings of a novel established molecular diagnostic technique for the prediction of malignant transformation in leukoplakia. Mol Med Report 2009;2:947-952.
24. Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini JC. Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int J Cancer 2000;86:749-751.
25. Fleskens SA, Bergshoeff VE, Voogd AC, van Velthuysen ML, Bot FJ, Speel EJ, Kremer B, Takes R, Slootweg P. Interobserver variability of laryngeal mucosal premalignant lesions: A histopathological evaluation. Mod Pathol 2011;24:892-898.
26. Brennan M, Migliorati CA, Lockhart PB, Wray D, Al-Hashimi I, Axell T, Bruce AJ, Carpenter W, Eisenberg E, Epstein JB, Holmstrup P, Jontell M, Nair R, Sasser H, Schifter M, Silverman B,ThongprasomK,ThornhillM,Warnakulasuriya S, van der Waal I. Management of oral epithelial dysplasia: A review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(Suppl. S19):e11-e12.
27. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Oral premalignant lesions: Is a biopsy reliable? J Oral Pathol Med 2007;36:262-266.
28. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: An overview of the literature. J Oral Pathol Med 2008;37:1-10.
29. Angiero F, Berenzi A, Benetti A, Rossi E, Del Sordo R, Sidoni A, Stefani M, Dessy E. Expression of p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral cavity. Anticancer Res 2008;28:2535-2539.
30. Bettendorf O, Piffko J, Bankfalvi A. Prognostic and predictive factors in oral squamous cell cancer: Important tools for planning individual therapy? Oral Oncol 2004;40:110-119.
31. Feng CJ, Li HJ, Li JN, Lu YJ, Liao GQ. Expression of Mcm7 and Cdc6 in oral squamous cell carcinoma and precancerous lesions. Anticancer Res 2008;28:3763-3769.
32. Gandolfo M, Keszler A, Lanfranchi H, Itoiz ME. Increased subepithelial vascularization and VEGF expression reveal potentially malignant changes in human oral mucosa lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:486-493.
33. Nasser W, Flechtenmacher C, Holzinger D, Hofele C, Bosch FX. Aberrant expression of p53, p16(INK4a) and Ki-67 as basic biomarker for malignant progression of oral leukoplakias. J Oral Pathol Med 2011;40:629-635.
34. Schaaij-Visser TB, Bremmer JF, Braakhuis BJ, Heck AJ, Slijper M, van der Waal I, Brakenhoff RH. Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. Oral Oncol 2010;46:123-127.
35. Ogmundsdottir HM, Bjornsson J, Holbrook WP. Role of TP53in the progression of pre-Malignant and malignant oral mucosal lesions. A follow-Up study of 144 patients. J Oral Pathol Med 2009;38:565-571.
36. Oliveira LR, Ribeiro-Silva A. Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2011;40:298-307.
37. Vairaktaris E, Yapijakis C, Derka S, Vassiliou S, Serefoglou Z, Vylliotis A,Wiltfang J, Springer I, Nkenke E, Kessler P, Neukam FW. Association of platelet glycoprotein Ia polymorphismwith minor increase of risk for oral cancer. Eur J Surg Oncol 2006;32:455-457.
38. Vairaktaris E, Yapijakis C, Yiannopoulos A,Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Critselis E, Avgoustidis D, Neukam FW, Patsouris E. Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol Rep 2007;17:963-968.
39. Pastorcic-Grgic M, Sarcevic B, Dosen D, Juretic A, Spagnoli GC, GrgicM. Prognostic value ofMAGE-A and NY-ESO-1 expression in pharyngeal cancer. Head Neck 2010;32:1178-1184.
40. Rapidis AD, Wolf GT. Immunotherapy of head and neck cancer: Current and future considerations. J Oncol 2009;2009:1-11.